Atara Biotherapeutics (ATRA) Receivables - Net (2020 - 2025)

Atara Biotherapeutics' Receivables - Net history runs 6 years deep, the most recent figure standing at $1.3 million for Q4 2025.

• Quarterly Receivables - Net fell 15.45% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 million (down 15.45% YoY) and the FY2025 annual result came in at $1.3 million, down 15.45% from the prior year.
• Receivables - Net was $1.3 million for Q4 2025 at Atara Biotherapeutics, down from $1.9 million in the prior quarter.
• Across five years, Receivables - Net topped out at $40.2 million in Q4 2022 and bottomed at $163000.0 in Q3 2023.
• A 5-year average of $8.3 million and a median of $1.3 million in 2024 frame the typical range for Receivables - Net.
• Peak annual rise in Receivables - Net reached 8926.2% in 2024, while the deepest fall reached 95.65% in 2024.
• Atara Biotherapeutics' Receivables - Net stood at $986000.0 in 2021, then soared by 3979.21% to $40.2 million in 2022, then fell by 15.2% to $34.1 million in 2023, then tumbled by 95.65% to $1.5 million in 2024, then decreased by 15.45% to $1.3 million in 2025.
• Business Quant data shows ATRA's Receivables - Net at $1.3 million in Q4 2025, $1.9 million in Q3 2025, and $8.9 million in Q1 2025.